Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China

PURPOSE: To evaluate the cost-utility of empagliflozin, in addition to best available standard care (BASC), for the treatment of adult patients with T2DM at high cardiovascular risk from the Chinese healthcare system perspective. METHODS: A Microsoft Excel-based patient-level simulation model, based...

Descripción completa

Detalles Bibliográficos
Autores principales: Men, Peng, Liu, Tianbi, Zhai, Suodi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431175/
https://www.ncbi.nlm.nih.gov/pubmed/32848438
http://dx.doi.org/10.2147/DMSO.S266901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431175/
https://www.ncbi.nlm.nih.gov/pubmed/32848438
http://dx.doi.org/10.2147/DMSO.S266901

Ejemplares similares